Mi Seon Kang Selected Research

Mi Seon Kang Research Topics

Disease

16	Neoplasms (Cancer) 01/2021 - 06/2004
4	Colonic Neoplasms (Colon Cancer) 12/2015 - 10/2014
3	Neoplasm Metastasis (Metastasis) 06/2020 - 01/2015
3	Lymphatic Metastasis 01/2015 - 09/2012
2	Body Weight (Weight, Body) 12/2021 - 04/2013
2	Acute Kidney Injury (Acute Renal Failure) 12/2021 - 12/2020
2	Breast Neoplasms (Breast Cancer) 01/2017 - 09/2014
2	Stomach Neoplasms (Stomach Cancer) 10/2016 - 01/2015
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2015 - 09/2012
2	Adenocarcinoma 01/2015 - 06/2014
1	Pneumonia (Pneumonitis) 01/2022
1	Necrosis 12/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Reperfusion Injury 12/2020
1	Lupus Nephritis 07/2020
1	Colorectal Neoplasms (Colorectal Cancer) 06/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 11/2019
1	Phenylketonurias (Phenylketonuria) 11/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2019
1	Endometrial Neoplasms (Endometrial Cancer) 04/2018
1	Cicatrix (Scar) 01/2017
1	Fibrosis (Cirrhosis) 01/2017
1	Glaucoma 01/2017
1	Inflammation (Inflammations) 01/2017
1	Lung Neoplasms (Lung Cancer) 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017
1	Oropharyngeal Neoplasms 09/2015
1	Uveitis 05/2015
1	Hypoxia (Hypoxemia) 04/2015
1	Ischemia 04/2015
1	Anemia 02/2015
1	Carcinogenesis 01/2015
1	Margins of Excision 12/2013
1	Rectal Neoplasms (Rectal Cancer) 12/2013
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 04/2013

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 04/2018 - 01/2012
3	15-hydroxyprostaglandin dehydrogenaseIBA 12/2021 - 06/2014
3	Therapeutic UsesIBA 03/2015 - 05/2009
2	Dinoprostone (PGE2)FDA Link 12/2021 - 06/2014
2	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 12/2021 - 04/2005
2	Oxidoreductases (Dehydrogenase)IBA 12/2020 - 01/2015
2	Biomarkers (Surrogate Marker)IBA 04/2018 - 01/2017
2	Biological ProductsIBA 10/2015 - 09/2012
2	ArsenicIBA 04/2013 - 05/2009
2	Arsenic Trioxide (Trisenox)FDA Link 04/2013 - 05/2009
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2022
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2022
1	InterferonsIBA 01/2022
1	Contrast MediaIBA 12/2021
1	IodineIBA 12/2021
1	Lipocalin-2IBA 12/2021
1	Adenosine Monophosphate (AMP)IBA 12/2021
1	Alprostadil (Muse)FDA LinkGeneric 12/2021
1	BromidesIBA 12/2021
1	iodixanol (Visipaque)FDA Link 12/2021
1	antineoplaston A10 (A 10)IBA 12/2021
1	Phosphates (Orthophosphate)IBA 12/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	SW033291IBA 12/2020
1	Complement System Proteins (Complement)IBA 07/2020
1	N 30IBA 06/2020
1	Pharmaceutical PreparationsIBA 06/2020
1	sapropterin (tetrahydrobiopterin)FDA Link 11/2019
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2019
1	sepiapterin reductaseIBA 11/2019
1	Protein Isoforms (Isoforms)IBA 04/2018
1	SaltsIBA 01/2017
1	lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA 01/2017
1	NecroX-5IBA 01/2017
1	CalciumIBA 01/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017
1	SolutionsIBA 01/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	Adenosine-5'-(N-ethylcarboxamide) (NECA)IBA 10/2016
1	ChemokinesIBA 05/2015
1	CytokinesIBA 05/2015
1	AntioxidantsIBA 04/2015
1	NADPH Oxidases (NAD(P)H oxidase)IBA 04/2015
1	Protective AgentsIBA 04/2015
1	Formaldehyde (Formol)FDA Link 01/2015
1	ParaffinIBA 01/2015
1	ProstaglandinsIBA 01/2015
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2015
1	Urokinase Plasminogen Activator ReceptorsIBA 10/2014
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 10/2014
1	EnzymesIBA 10/2014
1	CarcinogensIBA 06/2014
1	Cisplatin (Platino)FDA LinkGeneric 04/2013
1	incobotulinumtoxinA FDA Link 04/2013
1	Troleandomycin (TAO)FDA Link 04/2013

Therapy/Procedure

3	Therapeutics 01/2022 - 05/2009
3	Radiotherapy 01/2021 - 05/2009
3	Drug Therapy (Chemotherapy) 12/2015 - 04/2005
3	Adjuvant Chemotherapy 12/2015 - 02/2015
1	Filtering Surgery 01/2017
1	Injections 01/2017
1	Chemoradiotherapy 09/2015
1	Gastrectomy 01/2015
1	Immunotherapy 09/2014
1	Contraindications 12/2013